Yixintang Pharmaceutical Group Co., Ltd.

SZSE:002727 주식 보고서

시가총액: CN¥8.6b

Yixintang Pharmaceutical Group 미래 성장

Future 기준 확인 3/6

Yixintang Pharmaceutical Group is forecast to grow earnings and revenue by 48.5% and 13% per annum respectively. EPS is expected to grow by 48.2% per annum. Return on equity is forecast to be 11.7% in 3 years.

주요 정보

48.5%

수익 성장률

48.2%

EPS 성장률

Consumer Retailing 수익 성장42.3%
매출 성장률13.0%
향후 자기자본 수익률11.7%
애널리스트 커버리지

Good

마지막 업데이트01 Nov 2024

최근 미래 성장 업데이트

Recent updates

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15
These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29
Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13
Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27
Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03
Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15
Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06
Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

수익 및 매출 성장 예측

SZSE:002727 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202624,7049921,9851,91710
12/31/202521,7218501,9081,95010
12/31/202418,6474351,2511,4013
9/30/202418,1571561,7622,015N/A
6/30/202418,0103272,0862,355N/A
3/31/202418,0445521,9852,269N/A
12/31/202317,3805491,8622,115N/A
9/30/202318,2191,0191,9712,361N/A
6/30/202318,1421,0962,2342,553N/A
3/31/202317,8721,0702,4022,733N/A
1/1/202317,4321,0102,1482,497N/A
9/30/202216,1158352,1252,509N/A
6/30/202215,8518161,5371,947N/A
3/31/202215,1548401,2951,668N/A
1/1/202214,5879221,4001,792N/A
9/30/202113,9169508151,120N/A
6/30/202113,329897610928N/A
3/31/202112,998846690988N/A
12/31/202012,6567907531,033N/A
9/30/202012,0567248271,023N/A
6/30/202011,4486831,0771,257N/A
3/31/202010,9786339841,185N/A
12/31/201910,479604776983N/A
9/30/201910,2195878381,017N/A
6/30/20199,945566719892N/A
3/31/20199,585565828988N/A
1/1/20199,176521480636N/A
9/30/20188,768525481619N/A
6/30/20188,391499N/A579N/A
3/31/20188,116457N/A330N/A
12/31/20177,751423N/A391N/A
9/30/20177,316386N/A166N/A
6/30/20176,949373N/A44N/A
3/31/20176,584345N/A134N/A
12/31/20166,249353N/A193N/A
9/30/20165,971379N/A124N/A
6/30/20165,774369N/A220N/A
3/31/20165,600361N/A163N/A
12/31/20155,321346N/A187N/A
9/30/20155,080323N/A234N/A
6/30/20154,854314N/A58N/A
3/31/20154,589310N/A34N/A
12/31/20144,428297N/A176N/A
9/30/20144,236292N/A211N/A
6/30/20143,995279N/A228N/A
3/31/20143,792253N/A284N/A
12/31/20133,547241N/A228N/A

애널리스트 미래 성장 예측

수입 대 저축률: 002727's forecast earnings growth (48.5% per year) is above the savings rate (2.9%).

수익 vs 시장: 002727's earnings (48.5% per year) are forecast to grow faster than the CN market (25.8% per year).

고성장 수익: 002727's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: 002727's revenue (13% per year) is forecast to grow slower than the CN market (14% per year).

고성장 수익: 002727's revenue (13% per year) is forecast to grow slower than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 002727's Return on Equity is forecast to be low in 3 years time (11.7%).

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y